UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/584,982	04/02/2007	Robin Kurfurst	15675P620	2408
	7590 10/15/200 off, Taylor & Zafman	EXAMINER		
12400 Wilshire Boulevard, 7th floor			GIBBS, TERRA C	
Los Angeles, CA 90025			ART UNIT	PAPER NUMBER
			1635	
			MAIL DATE	DELIVERY MODE
			10/15/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/584,982	KURFURST ET AL.		
Examiner	Art Unit		
TERRA C. GIBBS	1635		

	TERRA C. GIBBS	1635	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>03 October 2008</u> FAILS TO PLACE THIS A	PPLICATION IN CONDITION FOR	R ALLOWANCE.	
The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperior Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A replies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Ar no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (i) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)	dvisory Action, or (2) the date set forth hter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extraction date of the structure of	on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in complifiling the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. X The proposed amendment(s) filed after a final rejection, b	out prior to the date of filing a brief	will not be entered be	cause
(a) ☐ They raise new issues that would require further cor			oaase
(b) They raise the issue of new matter (see NOTE below	•	. — , ,	
(c) They are not deemed to place the application in bett appeal; and/or	er form for appeal by materially rec	ducing or simplifying th	ne issues for
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: See Continuation Sheet. (See 37 CFR 1.13	16 and 41.33(a)).		
 The amendments are not in compliance with 37 CFR 1.12 Applicant's reply has overcome the following rejection(s): 		mpliant Amendment (I	PTOL-324).
 Applicant's reply has overcome the following rejection(s). Newly proposed or amended claim(s) would be all non-allowable claim(s). 		timely filed amendmer	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 38 and 42-57. Claim(s) withdrawn from consideration:	·	l be entered and an ex	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10. 🔲 The affidavit or other evidence is entered. An explanation	n of the status of the claims after er	ntry is below or attach	ed.
REQUEST FOR RECONSIDERATION/OTHER			
 The request for reconsideration has been considered but See Continuation Sheet. 	does NOT place the application in	condition for allowan	ce because:
12. \square Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)		
13.			
	/Sean R McGarry/ Primary Examiner, Art U	nit 1635	

Continuation of 3. NOTE: The proposed amendment will not be entered because it raises new issues that would necessarily require further consideration and/or search. For example, claim 38 has been amended to recite, "a method for depigmenting or bleaching human skin, body hair and/or hair of the head of a subject to lighten the color for purely cosmetic purposes comprising the topical application to the skin, body hair and/or hair of the head of said subject of a cosmetic composition comprising at least one oligonucleotide containing between 7 and 25 nucleotides, capable of specifically hybridising with genes or gene products coding for protein kinase C beta 1 (PKC beta-1)". The limitations, "to lighten the color for purely cosmetic purposes" and "to the skin, body hair and/or hair of the head of said subject" have never been recited before. Because these limitations have never been specifically considered during the prosecution history of this case, search and examination of these limitations would necessarily require further consideration and/or search.

Additionally, the proposed amendment will not be entered because it raises new issues that would necessarily require further consideration and/or search. For example, claim 57 has been amended to recite, "a method for the treatment of regional hyper-pigmentation by melanocyte hyperactivity such as idiopathic melasma, local hyper-pigmentation by benign melanocyte hyperactivity and proliferation such as pigmentary age spots (actinic lentigo), accidental hyper-pigmentation such as photosensitization or post-lesion healing in a subject in need thereof, comprising the topical application to the hyperpigmented skin areas of said subject a topical pharmaceutical composition comprising at least one oligonucleotide containing between 7 and 25 nucleotides, capable of specifically hybridising with genes or gene products coding for protein kinase C beta 1 (PKC beta-1)". The limitations, "a subject in need thereof" and "the hyperpigmented skin areas" have never been recited before. Because these limitations have never been specifically considered during the prosecution history of this case, search and examination of these limitations would necessarily require further consideration and/or search

Continuation of 11. does NOT place the application in condition for allowance because: The request addresses the claims as amended. However, the claims, as amended, have not been entered on the record.